Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy~* Histological or cytological confirmation of ER+/ HER2- breast cancer~* Postmenopausal women~* No prior treatment for metastatic breast cancer~Exclusion Criteria:~* Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)~* Patients who had received prior hormonal or any other systemic therapy for metastatic breast cancer. Patients might have received prior neoadjuvant or adjuvant endocrine therapy. In the case of neoadjuvant or adjuvant NSAI (letrozole/anastrozole) therapy patients must have completed therapy at least 1 year prior to study enrollment.~* Previous treatment with mTOR inhibitors.~* Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).~Other protocol-defined inclusion/exclusion criteria might apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus+letrozole/exemestane (first line and second line treatment) (Type: EXPERIMENTAL): Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)

Based on this trial design, predict the completion outcome and termination type (if applicable).